Intertek Opens New Laboratory in Manchester, UK
News Sep 25, 2015
Intertek has opened a 10,000 ft² bioanalytical and biopharmaceutical characterisation facility to deliver world-class scientific services to support the growing pipeline of biologics medicines such as monoclonal antibodies currently in development by clients around the globe.
This facility brings expanded capacity to create 30,000 ft2 of analytical and bioanalytical laboratories at Intertek’s Manchester-based Centre of Excellence for Biologics. The new bioanalysis, immunogenicity and characterisation capability will help drug companies to ensure that biologics medicines such as monoclonal antibodies (mAbs), recombinant proteins and vaccines are safe and effective to treat heart disease, cancer-related diseases such as leukemia or melanoma and other chronic ailments.
Chetan Parmar, Senior Vice President of Intertek Life Sciences said: “Intertek is highly committed to helping our clients to navigate the many technical challenges associated with bringing a biological medicine to market. This investment is key to providing the level of resource required to meet the ever increasing demand for our expertise and experience. Among the exciting projects now starting at this lab is testing of novel monoclonal antibody therapeutics, as well as antibody drug conjugates, which are highly complex yet offer great potential for a range of difficult-to-treat cancers.”
Ashleigh Wake, Intertek Biopharmaceutical Services Leader said: “We are seeing a growing demand for contract safety and efficacy services for innovative antibody therapeutics which address previously un-met medical needs. There is also demand for comparability and characterization testing services for numerous monoclonal antibody biosimilars which are on the cusp of being launched over the next few years, as patents on drugs such as infliximab, trastuzumab and rituximab are set to expire in the US.“
Life Sciences Minister George Freeman said: “The impressive new Intertek laboratory underlines the importance of the Northern Powerhouse to the UK’s life sciences industry, which has already seen £3.5 billion of investment and the creation of 11,000 jobs since the Prime Minister launched the UK Strategy for Life Sciences in 2011.
“With its ability to bring twenty-first century medicines one step closer to NHS patients, this facility can drive the innovation and growth of the future, putting life sciences in the north-west firmly on the map,” George added.
Combining Different Malaria Vaccines Could Reduce Cases by 91%News
Using two experimental anti-malarial vaccines, which work in different ways, can greatly reduce the number of malaria infections in animal studies. Experimental vaccines, which independently achieve 48% and 68% reductions in malaria cases, can achieve 91% reduction when combined.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE